Advertisement

Topics

NonSmall Cell Lung Cancer Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500

10:29 EDT 5 Jul 2017 | BioPortfolio Report Blog

NonSmall Cell Lung Cancer Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide NonSmall Cell Lung Cancer Pipeline Review, H1 2017, provides an overview of the NonSmall Cell Lung Cancer Oncology pipeline landscape.

Nonsmall cell lung cancer NSCLC is the most common type of lung cancer. NSCLC is a cancer malignancy that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit sputum, fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide NonSmall Cell Lung Cancer Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for NonSmall Cell Lung Cancer Oncology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The NonSmall Cell Lung Cancer Oncology pipeline guide also reviews of key players involved in therapeutic development for NonSmall Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 49, 192, 176, 1, 11, 173, 20 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 13, 11, 1, 40 and 4 molecules, respectively.

NonSmall Cell Lung Cancer Oncology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of NonSmall Cell Lung Cancer Oncology.
The pipeline guide reviews pipeline therapeutics for NonSmall Cell Lung Cancer Oncology by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in NonSmall Cell Lung Cancer Oncology therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates NonSmall Cell Lung Cancer Oncology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for NonSmall Cell Lung Cancer Oncology

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for NonSmall Cell Lung Cancer Oncology.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding NonSmall Cell Lung Cancer Oncology pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: NonSmall Cell Lung Cancer Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "NonSmall Cell Lung Cancer Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...